Mylan NV (MYL)

38.87
0.14 0.36
NASDAQ : Health Technology
Prev Close 38.73
Open 38.82
Day Low/High 38.56 / 39.12
52 Wk Low/High 29.39 / 47.82
Volume 3.12M
Avg Volume 4.43M
Exchange NASDAQ
Shares Outstanding 515.47M
Market Cap 19.89B
EPS 1.30
P/E Ratio 28.58
Div & Yield N.A. (N.A)

Latest News

Alibaba, Applied Materials, Chesapeake Energy: 'Mad Money' Lightning Round

Alibaba, Applied Materials, Chesapeake Energy: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Applied Materials, Chesapeake Energy, Endo Pharmaceuticals, Mylan Laboratories, JD.com, Alibaba and more.

Markets Shrug Off N. Korea: Cramer's 'Mad Money' Recap (Tuesday, June 12 2018)

Markets Shrug Off N. Korea: Cramer's 'Mad Money' Recap (Tuesday, June 12 2018)

Jim Cramer explains what U.S. markets are focusing on now that North Korean nuclear worries have faded.

Mylan Becomes #32 Most Shorted Nasdaq 100 Component, Replacing Netflix

Mylan Becomes #32 Most Shorted Nasdaq 100 Component, Replacing Netflix

The most recent short interest data has been released for the 05/31/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Americares Honors Mylan With Power Of Partnership Award

Americares Honors Mylan With Power Of Partnership Award

Award Presented at HDA Business and Leadership Conference

Senate Panel Considers Bill Aimed at Getting Generic Drugs to Market Faster

Senate Panel Considers Bill Aimed at Getting Generic Drugs to Market Faster

A healthcare bill supported on both sides of the aisle was held up until Sen. Chuck Grassley talked with pharma companies.

Dow Finishes Slightly Lower as Nasdaq Jumps to Another Record Close

Dow Finishes Slightly Lower as Nasdaq Jumps to Another Record Close

Stocks are mixed Tuesday but traders continue to snap up tech stocks.

U.S. FDA Approves Mylan And Biocon's Fulphila™ (pegfilgrastim-jmdb), The First Biosimilar To Neulasta®

U.S. FDA Approves Mylan And Biocon's Fulphila™ (pegfilgrastim-jmdb), The First Biosimilar To Neulasta®

Fulphila is expected to be the first biosimilar pegfilgrastim available in the U.S. to help patients with nonmyeloid cancers reduce the risk of infection following myelosuppressive chemotherapy

Mylan To Present At Goldman Sachs 39th Annual Global Healthcare Conference

Mylan To Present At Goldman Sachs 39th Annual Global Healthcare Conference

HERTFORDSHIRE, England and PITTSBURGH, June 1, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.

FDA Moves to Make Life Easier for Generic Drug Companies

FDA Moves to Make Life Easier for Generic Drug Companies

Following up on a pledge to accelerate generic drugs into the marketplace to stoke price competition, the agency signals pending reform of the Risk Evaluation and Mitigation Strategy.

Allergan's Meury Talks Market Expansion in Aesthetics

Allergan's Meury Talks Market Expansion in Aesthetics

The chief commercial officer's appearance at a Bank of America healthcare conference came a day after Allergan competitor Evolus said it had received a complete response letter regarding its application for Botox rival DWP-450.

Mylan And West Virginia University Join Forces To Inspire West Virginia Youth Through STEM-CARE

Collaboration aims to demystify STEM and broaden its perceived application

A Mom's Mother's Day Message to Wall Street: 'Enough Already'

A Mom's Mother's Day Message to Wall Street: 'Enough Already'

A Mother's Day message to Wall Street. Why are women and mom's still lagging when it comes to leadership and pay parity. Yes. it's 2018. Watch videos, listen to podcasts.

Mylan First-Quarter Revenue Misses Estimate Amid Lower Sales of Branded Product

Mylan First-Quarter Revenue Misses Estimate Amid Lower Sales of Branded Product

The EpiPen maker saw a 19% drop in North America net sales due in part to lower sales of branded products.

How to Play Trump's New 'War' With Iran: Market Recon

How to Play Trump's New 'War' With Iran: Market Recon

While the move higher for crude prices late Tuesday took the energy sector with it, defense and aerospace names saw benefit as well.

Mylan Becomes #20 Most Shorted Nasdaq 100 Component, Replacing QVCA

The most recent short interest data has been released for the 04/13/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Weekly Roundup

A strong Friday failed to keep markets in positive territory.

Teva Shows Progress on Restructuring But Investors Want More

Teva Shows Progress on Restructuring But Investors Want More

The Israel-based drugmaker reported first-quarter numbers that surpassed analysts' expectations but Wall Street wants to see more.

Aceto's Search for Deal May Be Slowed by DOJ Subpoena

Aceto's Search for Deal May Be Slowed by DOJ Subpoena

The tough news keeps coming at the generic drug company, which announced last week it was considering putting itself up for sale. Now the Justice Department wants a chat.

Mylan Presents Equivalence Data On Glatiramer Acetate Compared To Copaxone® At American Academy Of Neurology 70th Annual Meeting

Three posters highlight Mylan's rigorous Glatiramer Acetate development program

U.S. Senator Cory Booker Criticizes Pharma Companies in New Tax Report

U.S. Senator Cory Booker Criticizes Pharma Companies in New Tax Report

The Trump Administration cut corporate taxes and U.S. Senator Cory Booker hoped pharma companies would cut drug prices. That didn't happen and Booker's new analysis hammers those drug companies.

Mylan's Stock Gets Bump After Investor Day

Mylan's Stock Gets Bump After Investor Day

Following Wednesday's event, Leerink analyst Ami Fadia said she is 'incrementally more positive' on the drugmaker's pipeline and diversified business model and moved her rating to outperform.

Mylan Spotlights Diversification at Investor Day

Mylan Spotlights Diversification at Investor Day

The drug company generates about 60% of revenue outside the U.S.

American Medical Association Rejects Idea of Time Limits on Opioid Scripts

American Medical Association Rejects Idea of Time Limits on Opioid Scripts

While more than half the states in the U.S. have passed time limits on opioid prescription as a way to battle the epidemic, the AMA says that should be left up to the doctor and patient.

Biosimilar Pipeline Among Areas of Shareholder Focus at Mylan's Investor Day

Biosimilar Pipeline Among Areas of Shareholder Focus at Mylan's Investor Day

The pharmaceutical firm will conduct its investor day in New York City on April 11.

TheStreet Quant Rating: C+ (Hold)